Académique Documents
Professionnel Documents
Culture Documents
The outline of human vaccines had an incredible impact on global health system which
resulted in intense reduction of mortality and morbidity caused by numerous diseases.
Vaccines have led to some of the greatest public health achievements ever, including the
eradication of naturally occurring smallpox from the globe and the near eradication of polio.
This prophylaxis had a long journey through various roads and tunnels to become the
humanities key achievement. Despite of the fact, that its mechanism of action remained
unclear for centuries. New vaccines coined up in nineteenth century and after the expanded
In recent years peptides have emerged as the considerable vaccine candidate owning to their
simple and cost efficient production & development process. Peptides are recognized for
being highly selective and efficacious and, at the same time, relatively safe and well
tolerated. Given their attractive pharmacological profile and intrinsic properties, peptides
represent an excellent starting point for the design of novel therapeutics. Several peptide
vaccines are now being designed and are encountering phase I and phase II clinical trials.
Peptide vaccines include one or more short or long amino acids sequences, as an antigen
combined with a vaccine adjuvant. Thus they fall in the broad category of defined antigen
vaccines, along with the vaccines using proteins, protein sub units, DNA and RNA. They
remain the most immunogenic approaches based on the measures of T-cell responses. Peptide
immunogenicity is influenced by the way in which peptides are presented to the immune
system, underscoring the need for multifunctional delivery systems that couple antigen and
adjuvant into a single construct.
Cancer immunotherapy by peptide vaccines is one of most emerging and significant segment
that could help pharmaceutical companies to generate more revenues and help patients to
alleviate their medical condition. Peptide vaccine for treatment of metastatic prostate
cancer has been introduced in global market. This segment has tendency towards clinical
trials as compared to marketed products. Most of the novel products are at different stages of
clinical trials which would be introduced in global market in coming years.
Page 1
technology due to which they are still not available in market. But confidently these drugs are
going to overcome the all hurdles and will become the best suitable candidates in drug
market.
peptides, target DCs and PRR agonists. Combinations of carrier with TLR agonists provide new
advantages of their cytokine production in enhancing immune response.This is already evident
that in ongoing clinical trials that the benefits of using such vaccines will be large however
safety concerns with diseases like cancer and HIV are still under critical observations. With
the growing knowledge of immunological mechanism of adjuvant action, including identifying
the role of specific signaling pathways peptide based vaccines are going to become more
attractive and more effective segment of therapeutics.
Although, the opinions of experts in this field are mixed, it is likely that with new product
approvals and advanced research, the field of active peptide immunotherapy is self-assured
for dramatic growth in the coming years. Using the gained knowledge and history of passive
immunotherapy development as guiding tool, the peptides will revolutionize the market with
modern treatment of varied diseases by the means of peptides vaccines.
Global Peptide Vaccine Market & Clinical Pipeline Outlook 2020 Report Highlights:
Page 2
Table of Contents
1. Peptide Vaccine: A Prologue to Sub-Unit Vaccines
1.1 Introduction
1.2 Glimpse of Antiquity
2. Need of Peptide Vaccines
2.1 Why Peptides More Desirable
2.2 Peptide Vaccines V/S Traditional Vaccines
3. Classification of Peptide Vaccines
3.1 On the Basis of Sources Obtained
3.2 On the Basis of Length
3.3 On the Basis of Epitopes
4. Designing & Production of Peptide Vaccine
4.1 Synthetic Peptide Vaccine
4.2 Selection of Peptide Antigen
4.3 Construction of Peptide Antigen
4.4 Chemical Synthesis of Peptide Vaccine
4.4.1 Solution Phase Synthesis (SPS)
4.4.2 Solid Phase Peptide Synthesis (SPPS)
5. Mechanism of Peptide Vaccine
5.1 Induction of Immune Response
5.1.1 Factors Affecting T-Cell Stimulation
5.1.2 Factors Affecting B-cell Stimulation
5.1.3 Factors Affecting T-helper Cells
For Sample Contact: neeraj@kuickresearch.com , +91-11-47067990
Page 3
Page 4
Page 5
Page 6
List of Figures
Figure 1-1: History of Vaccines
Figure 2-1: Peptides - Amino Acid & Proteins
Figure 2-2: Diversification of Vaccines
Figure 2-3: Sub-Unit Vaccines V/S Traditional Vaccines
Figure 3-1: Classification of Peptide Vaccine by Source
Figure 3-2: Classification on Basis of Length
Figure 3-3: On the Basis of Epitopes
Figure 4-1: Synthetic Peptide Manufacturing Process
Figure 4-2: Selection of Synthetic Immunogenic Constructs
Figure 4-3: Solid phase Peptide Synthesis v/s Solution Phase Technique.
Figure 4-4: Fmoc Cleavage
Figure 4-5: Boc Cleavage
Figure 5-1: Mechanism of Immune Activation of CD4+ and CD8+ T-Cells
Figure 5-2: Delivery System Pathways by Adjuvants
Figure 5-3: Liposome & the Modes of Chemically Different Antigen Incorporation.
Figure 6-1: TAAs on the Basis of Tissue Distribution
Figure 6-2: Vaccination via Peptide Loaded Dendritic Cells
Figure 6-3: Mechanism of Action of Sipuleucel-T
For Sample Contact: neeraj@kuickresearch.com , +91-11-47067990
Page 7
Page 8
Page 9